'I have a feeling': Trump-endorsed malaria drug fails to pass muster in small Chinese coronavirus study
Despite the FDA’s reluctance to endorse without definitive clinical trial data the decades-old anti-malarial drugs chloroquine and derivative hydroxychloroquine as treatments to combat the coronavirus scourge, in recent days President Trump has trumpeted his faith — on the basis of a ‘feeling’ — that the drugs would work. Now, a key analyst has found trial data that contradict the positive conclusions of a small Chinese study that researchers initially based on their enthusiasm on.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.